PRQR Company Profile and Key Details

Q: Who are the executives of PRQR?

Ms. Sheila SponseleeVice President & Head of People and OperationsMr. Daniel Anton de BoerFounder, Chief Executive Officer & Member of Management BoardDr. Gerard PlatenburgCo-Founder & Chief Scientific OfficerMs. Sarah Cue KielyVice President of Investor Relations & Corporation CommunicationsMr. Jurriaan DekkersChief Financial OfficerMs. Sandra van der KolkJr. Financial ControllerMr. Aniz Girach M.D.Chief Medical OfficerMr. Bart KleinSenior Vice President of Intellectual PropertyDr. Domenico Valerio Ph.D.Founder & Independent Chairman of Supervisory BoardMr. Rene K. BeukemaChief Corporation Devel. Officer, Gen. Counsel & Member of Management Board

NASDAQ : PRQR

ProQR Therapeutics NV

$1.54

0.03+1.99%

At Close 4:00 PM

61.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ProQR Therapeutics N.V. (PRQR) stock surged +1.99%, trading at $1.54 on NASDAQ, up from the previous close of $1.51. The stock opened at $1.50, fluctuating between $1.50 and $1.58 in the recent session.

Stock Snapshot

1.51

Prev. Close

162.23M

Market Cap

1.495

Day Low

-3.14

P/E Ratio

-0.49

EPS (TTM)

0.23

Cash Flow per Share

1.5

Open

105.35M

Number of Shares

1.575

Day High

62.43%

Free Float in %

0.53

Book Value

166.23K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	1.53	1.57	1.50	1.54	166.23K
Feb 24, 2026	1.44	1.55	1.44	1.51	272.2K
Feb 23, 2026	1.44	1.47	1.42	1.44	103.39K
Feb 20, 2026	1.43	1.48	1.42	1.44	249.63K
Feb 19, 2026	1.48	1.51	1.43	1.47	215.08K
Feb 18, 2026	1.45	1.58	1.42	1.49	416.39K
Feb 17, 2026	1.46	1.52	1.43	1.45	338.34K
Feb 13, 2026	1.41	1.54	1.41	1.46	354.93K
Feb 12, 2026	1.42	1.44	1.33	1.39	673.68K
Feb 11, 2026	1.49	1.55	1.42	1.42	186.94K
Feb 10, 2026	1.53	1.55	1.46	1.48	362.66K
Feb 09, 2026	1.52	1.55	1.45	1.47	218.43K
Feb 06, 2026	1.45	1.52	1.43	1.50	357.43K
Feb 05, 2026	1.55	1.58	1.45	1.46	294.77K
Feb 04, 2026	1.60	1.60	1.53	1.55	420.28K
Feb 03, 2026	1.58	1.61	1.55	1.59	357.12K
Feb 02, 2026	1.62	1.65	1.55	1.55	792.12K
Jan 30, 2026	1.61	1.65	1.60	1.62	443.64K
Jan 29, 2026	1.63	1.65	1.60	1.60	345.39K
Jan 28, 2026	1.67	1.69	1.61	1.62	691.47K

Contact Details

Leiden, 2333 Ck

Netherlands

https://www.proqr.com 318 816 67000

About Company

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current ProQR Therapeutics N.V. (PRQR) stock price?

ProQR Therapeutics N.V. (NASDAQ: PRQR) stock price is $1.54 in the last trading session. During the trading session, PRQR stock reached the peak price of $1.58 while $1.50 was the lowest point it dropped to. The percentage change in PRQR stock occurred in the recent session was 1.99% while the dollar amount for the price change in PRQR stock was $0.03.

PRQR's industry and sector of operation?

The NASDAQ listed PRQR is part of Biotechnology industry that operates in the broader Healthcare sector. ProQR Therapeutics N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRQR?

Ms. Sheila Sponselee
Vice President & Head of People and Operations
Mr. Daniel Anton de Boer
Founder, Chief Executive Officer & Member of Management Board
Dr. Gerard Platenburg
Co-Founder & Chief Scientific Officer
Ms. Sarah Cue Kiely
Vice President of Investor Relations & Corporation Communications
Mr. Jurriaan Dekkers
Chief Financial Officer
Ms. Sandra van der Kolk
Jr. Financial Controller
Mr. Aniz Girach M.D.
Chief Medical Officer
Mr. Bart Klein
Senior Vice President of Intellectual Property
Dr. Domenico Valerio Ph.D.
Founder & Independent Chairman of Supervisory Board
Mr. Rene K. Beukema
Chief Corporation Devel. Officer, Gen. Counsel & Member of Management Board

How PRQR did perform over past 52-week?

PRQR's closing price is 43.92% higher than its 52-week low of $1.07 where as its distance from 52-week high of $3.10 is -50.32%.

How many employees does PRQR have?

Number of PRQR employees currently stands at 166.

Link for PRQR official website?

Official Website of PRQR is: https://www.proqr.com

How do I contact PRQR?

PRQR could be contacted at phone 318 816 67000 and can also be accessed through its website. PRQR operates from Zernikedreef 9, Leiden, 2333 Ck, Netherlands.

How many shares of PRQR are traded daily?

PRQR stock volume for the day was 166.23K shares. The average number of PRQR shares traded daily for last 3 months was 525.39K.

What is the market cap of PRQR currently?

The market value of PRQR currently stands at $162.23M with its latest stock price at $1.54 and 105.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	166
Beta	0.2
Sales or Revenue	$6.38M
5Y Sales Change%	-0.446%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	166
Beta	0.2
Sales or Revenue	$6.38M
5Y Sales Change%	-0.446%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PRQR Company Profile and Key Details

ProQR Therapeutics NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook